In This Article:
Regenerative health company LifeNet Health has announced the launch of its newest bone allograft designed in collaboration with healthcare giant Johnson & Johnson MedTech as the company plans to make its entrance into the demineralised bone matrix (DBM) market.
Lifenet says that its bone allograft, dubbed PliaFX Pak, combines mineralised bone chips with precision-machined moldable demineralised fibres designed to give surgeons a means of addressing voids and defects in orthopaedic spine and trauma procedures.
Market research carried out by GlobalData found that the US bone grafts and substitutes market will generate $2.2bn in 2030 in the US, increasing at a compound annual growth rate (CAGR) of 3.2% from $1.6bn in 2020.
This newest addition to the PliaFX family of bone void fillers, which includes PliaFX Prime and PliaFX Strip, will be commercialised through Johnson & Johnson MedTech this month.
The company insists that its PliaFX Pak stands out due to its ease of handling with interlocking fibres within the mouldable graft that can be transferred quickly and easily to the surgical site, eliminating the need for the previously used one-by-one transfer associated with traditional bone.
The osteoconductive scaffold that forms within the gel has a large surface area and is an interconnected network of bone fibres and chips, supports cell attachment and is designed to promote bone and blood vessel formation.
Rich Rice, vice president of orthopedics at LifeNet Health said "LifeNet Health's advanced fibre technology in PliaFX Pak sets a new standard for bone graft handling and performance. This innovation provides surgeons with a superior option that not only meets clinical needs but also enhances surgical efficiency.”
The PliaFX line of products joins some of the company’s other offerings, including its decellularised placental membrane for wound healing, Matrion.
Elsewhere in the field of bone graft technology Massachusetts-based orthobiologic and spine-fusion firm, Bone Biologics Corporation, has announced that it has treated the first two patients in a pilot clinical study of its NB1 bone graft device. At the same time, UK-based medical device company Biocomposites has announced the initiation of two Phase II clinical trials of its pharmaceutical-grade calcium sulphate biodegradable bone graft, STIMULAN.
"LifeNet launches newest bone allograft gel with Johnson & Johnson" was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.